Kymera Therapeutics Inc — Cash Flow (NASDAQ:KYMR) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics Dividends

Quarterly Annual

Cash from operating activities 88.13 M128.95 M153.09 M102.83 M194.5 M232.89 M 232.89 M Cash from investing activities 422.59 M99.83 M20.52 M139.89 M404.08 M521.06 M 521.06 M Cash from financing activities 289.26 M250.28 M153 M4.19 M608.85 M990.71 M 990.71 M Free cash flow 79.03 M127.35 M150.25 M68.35 M181.66 M231.44 M 231.44 M

Nouvelles

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway

Morgan Stanley réduit l’objectif de cours de Kymera Therapeutics

Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress

RBC Capital relève l’objectif de cours de Kymera Therapeutics

RBC Capital raises Kymera Therapeutics price target on pipeline progress

RBC Capital raises Kymera Therapeutics price target on pipeline

Stifel réitère sa recommandation d’achat sur Kymera Therapeutics à 114$

Stifel reiterates Buy rating on Kymera Therapeutics stock at $114

Kymera Q4 2025 slides: pipeline advances despite revenue miss

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Kymera Therapeutics lance une offre d’actions de 500 millions de dollars

Kymera Therapeutics launches $500 million at-the-market stock offering